Porter v. Kijakazi

District Court, D. Minnesota·Decided March 31, 2022·No. 0:20-cv-01586·Unknown

Opinion

UNITED STATES DISTRICT COURT DISTRICT OF MINNESOTA

David A. P., Case No. 20-cv-1586 (TNL)

Plaintiff,

v. ORDER

Kilolo Kijakazi, Acting Commissioner of Social Security, 1

Defendant.

Fay E. Fishman, Peterson & Fishman, 2915 South Wayzata Boulevard, Minneapolis, MN 55405 (for Plaintiff); and

Michael Moss and Tracey Wirmani, Special Assistant United States Attorneys, Social Security Administration, 1301 Young Street, Suite 350, Mailroom 104, Dallas, TX 75202 (for Defendant).

I. INTRODUCTION Plaintiff David A. P. brings the present case, contesting Defendant Commissioner of Social Security’s denial of disability insurance benefits (“DIB”) under Title II of the Social Security Act, 42 U.S.C. § 401 et seq., and supplemental security income (“SSI”) under Title XVI of the same, 42 U.S.C. § 1381 et seq. The parties have consented to a final judgment from the undersigned United States Magistrate Judge in accordance with 28 U.S.C. § 636(c), Fed. R. Civ. P. 73, and D. Minn. LR 72.1(c).

1 The Court has substituted Acting Commissioner Kilolo Kijakazi for Andrew Saul. A public officer’s “successor is automatically substituted as a party” and “[l]ater proceedings should be in the substituted party’s name.” Fed. R. Civ. P. 25(d). This matter is before the Court on the parties’ cross motions for summary judgment. ECF Nos. 16, 19. Being duly advised of all the files, records, and proceedings herein, IT

IS HEREBY ORDERED that Plaintiff’s Motion for Summary Judgment, ECF No. 16, is DENIED and the Commissioner’s Motion for Summary Judgment, ECF No. 19, is GRANTED. II. PROCEDURAL HISTORY On August 3, 2017, Plaintiff applied for DIB and SSI asserting that he has been disabled since April 2017 due to back and neck pain, a cognitive disorder, depression,

attention deficit hyperactivity disorder (“ADHD”), and seizures. Tr. 13, 257-69. Plaintiff’s applications were denied initially and again upon reconsideration. Tr. 180-84, 191-96. Plaintiff appealed the reconsideration of his DIB and SSI determinations by requesting a hearing before an administrative law judge (“ALJ”). Tr. 197-98. The ALJ held a hearing in July 2019, and issued an unfavorable decision. Tr. 10-78. After receiving

an unfavorable decision from the ALJ, Plaintiff requested review from the Appeals Council, which was denied. Tr. 1-6. Plaintiff then filed the instant action, challenging the ALJ’s decision. Compl., ECF No. 1. The parties have filed cross motions for summary judgment. ECF Nos. 16, 19. This matter is now fully briefed and ready for a determination on the papers. III. MEDICAL RECORDS Plaintiff has a history of neurocognitive disorder, ADHD, and neck and back pain.

See, e.g., Tr. 399, 412, 423, 505, 510, 596. Among other medications, Plaintiff has been prescribed Keppra2 and naproxen.3 See, e.g., Tr. 419-20, 424, 545-46. A. Mental Impairments 1. 2013 In late October 2013, Plaintiff was seen by psychologist Curtis Siegel for a psychotherapy intake session after bringing up concerns with his ability to concentrate. Tr.

391, 397. Plaintiff reported that he started a welding program at North Hennepin Technical College. Tr. 391. While he was passing his tests, he believed that was only because they were open book, online exams. Tr. 391. Plaintiff reported that as a child, he had a seizure disorder, right-hand tremor, mild hydrocephalus, and learning disabilities. Tr. 391. He described difficulties doing homework, paying attention, and having his mind wander. Tr.

391. He was directed to complete the “Semistructured Interview for Adult ADHD” and return for therapy with Siegel. Tr. 393. Plaintiff was seen by Siegel in November and December for ADHD therapy. Tr. 395-401. Based on Plaintiff’s history of being diagnosed with ADHD as a child, reported difficulties with distractibility and having trouble focusing, current problems in his college

program, and his responses in the Semistructured Interview for Adult ADHD which

2 Keppra is a brand name for levetiracetam, a medication used to control and treat seizures “by decreasing abnormal excitement in the brain.” Levetiracetam, MedlinePlus, Nat’l Lib. of Med., https://medlineplus.gov/druginfo/meds/ a699059html (last accessed Mar. 23, 2022). 3 Naproxen is a medication “used to relieve pain, tenderness, swelling, and stiffness.” Naproxen, MedlinePlus, Nat’l Lib. of Med., https://medlineplus.gov/druginfo/meds/a681029.html (last accessed Mar. 23, 2022). highlighted problems with inattentiveness, Siegel concluded that Plaintiff met the criteria for ADHD, predominantly inattentive type. Tr. 399. Plaintiff was not interested with

continuing therapy. Tr. 399. He was directed to schedule a psychiatry intake and stop drinking alcohol. Tr. 401. Siegel told Plaintiff it would be highly unlikely that a physician would prescribe him ADHD medication given that he reported having 2-4 pints of alcohol per week, though not every week. Tr. 401. 2. 2014 In February 2014, Plaintiff was seen by Richard Peterson, M.D. Tr. 402. Dr.

Peterson reviewed Plaintiff’s childhood records from the University of Minnesota pediatric neurology unit in the 1970s, which showed a history of hydrocephalus, an abnormal electroencephalograph (“EEG”) that revealed bifrontal spikes, and that Plaintiff had been prescribed Dilantin.4 Tr. 402. Plaintiff required special education and had special classes for learning development throughout high school. Tr. 402. Dr. Peterson noted that “[i]t is

very possible that” Plaintiff’s memory problems and difficulty learning new information “simply is an extension of what he has dealt with throughout his life.” Tr. 403. But given Plaintiff’s reports about feeling like his memory is getting worse overtime and the prior abnormal EEG, Dr. Peterson recommended that Plaintiff obtain an EEG for further evaluation. Tr. 403.

Plaintiff then completed a head MRI and EEG. Tr. 447, 448. The EEG was deemed to be abnormal “because of the bursts of generalized (left temporal predominant)

4 Dilantin is a brand name for phenytoin injections, a medication used to treat seizures. Phenytoin Injection, MedlinePlus, Nat’l Lib. of Med., https://medlineplus.gov/druginfo/meds/a619062html (last accessed Mar. 23, 2022). polymorphic sharp as well as slow activity and multifocal sharp waves and spikes.” Tr. 449. Given that the EEG showed epileptiform discharges concerning for seizure potential,

Dr. Peterson started Plaintiff on Keppra, a medication that treats seizures, at a dose of 500 mg. Tr. 419-20. Plaintiff was again seen by Dr. Peterson in April. Tr. 419. Dr. Peterson observed that Plaintiff was tolerating his current dose of Keppra well and had no significant side effects, but Plaintiff reported that he had not noticed a change in memory overall. Tr. 419. Dr. Peterson increased Plaintiff’s dose to 1000 mg and referred Plaintiff for formal

neuropsychological testing. Tr. 420. Dr. Peterson noted that he “think[s] the real issue here is whether or not what [Plaintiff] is experiencing is an extension of his lifelong memory and learning difficulties, or if there are other contributing factors. [Plaintiff] did have a significant history of alcohol intake which . . . can also have a significant impact on memory and cognition.” Tr. 420.

Plaintiff then completed his neuropsychological testing with neuropsychologist Terry Barclay in late April. Tr.

Free access — add to your briefcase to read the full text and ask questions with AI

Porter v. Kijakazi, (mnd 2022).

Porter v. Kijakazi (Porter v. Kijakazi) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Halverson v. Astrue
600 F.3d 922 (Eighth Circuit, 2010)
Martise v. Astrue
641 F.3d 909 (Eighth Circuit, 2011)
McCoy v. Astrue
648 F.3d 605 (Eighth Circuit, 2011)
Perkins v. Astrue
648 F.3d 892 (Eighth Circuit, 2011)
Boettcher v. Astrue
652 F.3d 860 (Eighth Circuit, 2011)
David Perks v. Michael J. Astrue
687 F.3d 1086 (Eighth Circuit, 2012)
Terri Anderson v. Michael J. Astrue
696 F.3d 790 (Eighth Circuit, 2012)
Howe v. Astrue
499 F.3d 835 (Eighth Circuit, 2007)
Medhaug v. Astrue
578 F.3d 805 (Eighth Circuit, 2009)
Davidson v. Astrue
578 F.3d 838 (Eighth Circuit, 2009)
Travis Chaney v. Carolyn W. Colvin
812 F.3d 672 (Eighth Circuit, 2016)
Samuel Buford v. Carolyn W. Colvin
824 F.3d 793 (Eighth Circuit, 2016)
Laura Julin v. Carolyn W. Colvin
826 F.3d 1082 (Eighth Circuit, 2016)
Marcus Hensley v. Carolyn W. Colvin
829 F.3d 926 (Eighth Circuit, 2016)
Theresa Aguiniga v. Carolyn W. Colvin
833 F.3d 896 (Eighth Circuit, 2016)